BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10726046)

  • 41. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
    Chim CS; Kwong YL; Lie AK; Ma SK; Chan CC; Wong LG; Kho BC; Lee HK; Sim JP; Chan CH; Chan JC; Yeung YM; Law M; Liang R
    Arch Intern Med; 2005 Dec 12-26; 165(22):2651-8. PubMed ID: 16344424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.
    Randi ML; Bertozzi I; Rumi E; Elena C; Finazzi G; Vianelli N; Polverelli N; Ruggeri M; Vannucchi AM; Antonioli E; Lussana F; Tieghi A; Iurlo A; Elli E; Ruella M; Fabris F; Cazzola M; Barbui T
    Am J Hematol; 2014 Mar; 89(3):306-9. PubMed ID: 24265194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of essential thrombocythemia.
    Cervantes F
    Hematology Am Soc Hematol Educ Program; 2011; 2011():215-21. PubMed ID: 22160037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
    Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
    Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 49. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
    Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
    Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; van Vliet HH
    Blood Cells Mol Dis; 2006; 36(2):199-205. PubMed ID: 16510297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Essential thrombocythemia.
    Finazzi G; Harrison C
    Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
    Alvarez-Larrán A; Cervantes F; Bellosillo B; Giralt M; Juliá A; Hernández-Boluda JC; Bosch A; Hernández-Nieto L; Clapés V; Burgaleta C; Salvador C; Arellano-Rodrigo E; Colomer D; Besses C
    Leukemia; 2007 Jun; 21(6):1218-23. PubMed ID: 17519959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia.
    Edahiro Y; Ando J; Suzuki T; Fukumura Y; Masuda A; Sakayori S; Takeda J; Maruyama Y; Makino S; Itakura A; Komatsu N
    Intern Med; 2018 Dec; 57(24):3647-3650. PubMed ID: 30101937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
    Kc D; Falchi L; Verstovsek S
    Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
    Mazzucconi MG; Baldacci E; Latagliata R; Breccia M; Paoloni F; Di Veroli A; Cedrone M; Anaclerico B; Villivà N; Porrini R; Montefusco E; Andriani A; Montanaro M; Scaramucci L; Spadea A; Rago A; Cimino G; Spirito F; Santoro C
    Eur J Haematol; 2020 Sep; 105(3):335-343. PubMed ID: 32441419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.